gskmanagement-120421080717-phpapp01 (1).ppt

8/10/2019 gskmanagement-120421080717-phpapp01 (1).ppt

1/21

AN ORGANIZATION STUDY

GLAXOSMITHKLINEPresented by:-

Mr. Mehsum Ali

Mr. Ali Ather Mohsin

Mr.Mohammad Arif

Mr. Taj-ud-din

Mr. Muhammad Ali Hashmi


2/21

TOPICSTOCOVER

Introduction and Background

Vision and Mission

Product line

GSK Management Organizational Chart

Management Levels

SWOT Analysis

Porters Strategies

Questions and Answers


3/21

INTRODUCTIONANDBACKGROUND

GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often

abbreviated to GSK, is a global pharmaceutical,

biologics, vaccines and consumer healthcare

company headquartered in London, United

Kingdom. It is the world's Fourth largestpharmaceutical company measured by revenues

(after Johnson & Johnson, Pfizer & Roche.

GSKwas formed in 2000 by the merger of

GlaxoWellcome plc (formed from the acquisition ofWellcome plc by Glaxo plc), and SmithKline

Beecham plc (from the merger of Beecham plc, and

SmithKlineBeckman Corporation).


4/21


5/21

VISIONANDMISSION

The opportun i ty to make a

di f ference to the l ives o f bi l l ions of

people.

GlaxoSmithKline has a challenging

and inspiring mission their mission is

to improve the quality of human life by

enabling people to do more, feel better

and live longer


6/21

PRODUCTLINE


7/21

GSK MANAGEMENT

The company is managed by the Board of Directors

and the Corporate Executive Team.

The Board is comprised of executive and non-

executive directors who are responsible for their

corporate governance and ultimately accountable

for their activities, strategy and performance.

The Chief Executive Officer (CEO) is responsible

for the management of the business and is assisted

by the Corporate Executive Team that managestheir activities. Each member is responsible for a

specific part of the business.


8/21

ORGANIZATIONALCHARTBoard of Directors

Chairmain & CEO

Deput

chairman

ExecutiveDirectors

MarketingManagement

Dept.

StrategicManagement

Dept.

ProductManagement

Dept.

HumanResource

Dept.

Selection &Recruitment

Dept.

FinanceDepartment

Audit Dept.

QualityControle Dept.

Product LineQ.C. Dept

Product Q.C.Dept

SalesManagement

Dept.

National SalesDept.

ProviosionalSalels Dept.

Area SalesDept.

Trade Net Dept.

InternationalTrade Ins.

GeneralAdministration

Dept.

Planning &Finance

Dept.

Overseas &

DomesticBranch office

AdvisoryCommittee on

Administration

Development


9/21

MANAGEMENT LEVELS

The management levels of GSK

are as follows:-

Executive-LevelDirector-Level

Manager-Level

Staff


10/21

SWOT ANALYSIS

STRENGTHS

WEAKNESSES

OPPURTUNITIES

THREATS


11/21

Strengths:

Strong Management Team

Large Market Share

Highest research Products in Pakistan

Wide range of Products

Weaknesses:

No online presence in Pakistan

Strong focus on UK market (losing

opportunities in Pakistan)

Less checking on the sales

representatives for their working in field

Opportunities:Emerging markets and expansion abroad

Have great chance to cash its brand

name in the field of surgical market

GSK can be able to cash its name in

baby foods

Threats:Lower cost competitors or imports like

Chinese and Indian medicines etc

Patent expiry on drugs that generate

strong income

Increasing cost of drug trials (research)

and ever higher standards imposed by

national drug approvals bodies.


12/21

PORTERS STRATEGIES


13/21

TO GROW A DIVERSIFIED GLOBAL BUSINESS.

DELIVER VALUE PRODUCTS

SIMPLIFYING THE OPERATING MODEL

CHALLENGING AND INSPIRING MISSION

LONG TERM INCENTIVE PLAN


14/21

Increase growth in the pharmaceutical business in

its core market.

GSK is diversifying its business to bring balance in

product portfolio & go away from a reliance on

traditional markets.

GSK expects to generate future sales growth by

strengthening its core pharmaceutical business &

supplementing it with increased investment in

growth such as; vaccines, dermatology andconsumer health care.

Business expansion inn Japan

Build a leadership in dermatology.


15/21

Focusing on the best science

Focus on research and development

Diversifying the level of externalization in research

to focus on disease area, where GSK believe the

prospects for successful registration and launch ofdifferentiated medicines.


16/21

As GSK continue to change shape, so it is essential

that reduce the complexities in operating model,improve efficiencies and reduce cost.

Re-shape manufacturing


17/21

GSK has a challenging vision and mission is to

improve the quality of human life by making peopleto do more, feel better and live longer.


18/21

Long term incentive plan.

awards are made to executives under the

following long term incentive plan,

i) Deferred annual bonus planii) Performance share plan

Explanation: Deferred Annual bonus plan:

The deferred annual bonus planencourages long term shareholding, discourages

excessive risk taking and help focus on GSKS

key strategic priorities.


19/21

Performance share : the performance share plan

ensure focus on the delivery of GSKS strategic

priorities and long term share holders returns

relative to other pharmaceutical companies.


20/21

Meeting with DR. AHMED FARHAN

Questionnaire MANAGER AND STAFF

Interview DR. AHMED FARHAN


21/21

GSK annual report 2011.

www.gsk.com

Term report of GSK

Wikipedia,2011
http://www.gsk.com/http://www.gsk.com/

gskmanagement-120421080717-phpapp01 (1).ppt

Documents

Transcript of gskmanagement-120421080717-phpapp01 (1).ppt